Catalyst Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application increasing the indicated maximum daily dose of FIRDAPSE for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome. The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
- Catalyst Pharmaceuticals price target raised to $26 from $24 at H.C. Wainwright
- Catalyst Pharmaceutical’s Buyback: A Double-Edged Sword for Financial Health and R&D Investment?
- Catalyst Pharmaceuticals reports Q1 EPS 19c, consensus 17c
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update